Bio-Works’ order intake in the first quarter was 31,6 (6,2) MSEK, an increase of 25,4 MSEK. The order intake has been very strong in Europe, but region USA and Asia also showed positive development during the quarter.
Net sales in the first quarter were 9,0 (5,9) MSEK. Large deliveries to customers in Europe and the USA explain the sales increase.
Operating profit in the quarter was -7,8 (-12,2) MSEK compared with the first quarter 2024. The 24 MSEK cost reduction program has gone according to plan during the quarter. In addition, the positive development in sales and gross margin has had a positive impact on operating profit.
Personnel costs amounted to 7,8 (10,1) MSEK. The lower personnel costs can be explained by personnel reductions in 2024.
The other external costs were 7,0 (7,0) MSEK, at the same level as last year. We continue to focus on keeping costs at current levels.
Profit for the first quarter amounted to -8,0 (-11,8) MSEK.
Earnings per share in the quarter amounted to -0,10(-0,30) SEK – before and after dilution.
Cash flow from operating activities was –4,4 (-12,3) MSEK
Cash and cash equivalents at the end of the period were 29,7 (27,3) MSEK.
Message from the CEO
We have entered 2025 with strong momentum and a clear focus. In the first months of the year, we are already seeing clear results from the collective efforts to build a more efficient and stronger Bio-Works. Costs remain under control, and we are delivering results in the form of growing order intake and improved margins. Our strategic initiative to streamline operations is bearing fruit, and its impact is visible throughout the organization.
Order intake reached a new record in the first quarter of 2025, amounting to SEK 31.6 million – the highest for any quarter in Bio-Works’ history, something we are proud of. Growth has remained strong beyond the end of the quarter, with additional orders totalling SEK 14.4 million in April. Our returning customers – a vital part of our business – continue to choose Bio-Works for our high product quality, reliable deliveries, and the personal and professional service we are known for.
Bio-Works' 2023 Annual Report describes the company's continued journey as it positions itself as the industry's preferred "tailor" of customized solutions, while implementing significant internal changes with the aim of creating an even more agile and focused organization that is adapted to prevailing market conditions.
An investment in Bio-Works allows participation in the expansive biotechnology sector but with a lower risk profile.
Bio-Works generates revenue in the early phases of a biotherapeutics' development, long before the approval of the drug substance.
There is a strong market demand for suppliers of chromatography resins who can offer alternatives to the few that have dominated the market for decades.
Bio-Works has the foundational cornerstones in place and is well-positioned for expansive growth without large investments in the near future.
